However, the mean change from baseline in all three nemolizumab groups at Week 1, and in the nemolizumab 0.5 mg/kg group at Week 4, was greater than that in the placebo group; moreover, there was a tendency for patients with higher serum IL-31 levels at screening to have greater pruritus VAS reductions following nemolizumab treatment. Here, IL31 is linked to Pruritus.